Moderna Sues Pfizer as Both Companies Drain the US Treasury

Moderna Sues Pfizer as Both Companies Drain the US Treasury

By Dr. Peter McCullough

On August 22, 2022, Pfizer and BioNTech announced they submitted the application to U.S. FDA for Emergency Use Authorization of their Omicron BA.4/BA.5-Adapted Bivalent COVID-19 vaccine.1 On June 29, 2022, Pfizer announced a new vaccine supply agreement with the U.S. government.2 Under the agreement, the U.S. government will receive 105 million doses (30 µg, 10 µg, and 3 µg).

This may include adult Omicron-adapted bivalent COVID-19 vaccines. The doses are planned to be delivered as soon as late summer 2022 and continue into the fourth quarter of this year. The U.S. government will pay the companies $3.2 billion upon receipt of the first 105 million doses. Under this agreement, the U.S. government also has the option to purchase up to 195 million additional doses, bringing the total number of potential doses to 300 million.

“As the virus evolves, this new agreement will help ensure people across the country have access to vaccines that may provide protection against current and future variants,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. Bourla has not acknowledged or explained the 1223 deaths that occurred within 90 days of the first release of his vaccine, as revealed in court-ordered documents.

Meanwhile, Moderna, Inc., recently announced that the U.S. government has secured 66 million doses of a Moderna COVID-19 vaccine booster candidate, mRNA-1273.222, the bivalent booster candidate containing Spikevax™ plus the Omicron BA.4/5 strain mRNA. The contract includes an award of up to $1.74 billion for the manufacture and delivery of 66 million doses of mRNA-1273.222, as well as options to purchase up to an additional 234 million doses of COVID-19 vaccine booster candidates from Moderna.

“We are pleased to extend our successful collaboration with the U.S. government,” said Stéphane Bancel, Chief Executive Officer of Moderna. Bancel is the billionaire CEO who previously led French Conglomerate BioMérieux in building the biosecurity level-4 annex to the Wuhan Institute of Virology. It is widely understood that this application will have no safety testing of the product for reactogenicity, carcinogenicity, or teratogenicity. Given this background, it should come as no surprise that Moderna has filed a patent infringement case against Pfizer.

This case may shed considerable light on the development of the mRNA vaccines that preceded the pandemic viral release for many years. No matter what happens with the lawsuit, for Americans, there will be no clinical trials for vaccine efficacy in humans. For the first time in regulatory history, a novel genetic product(s) has been pre-purchased by our government for use in Americans with no assurances whatsoever on safety or efficacy.

These acts of reckless regulatory malfeasance are unprecedented, and Americans should understand clearly, that administration of these vaccines, whether voluntary or under some form of duress such as an employment or school mandate, places the liability squarely on the person who accepts these shots into their body. We can expect for those taking more vaccine injections that 15% will develop a new medical disease or problem, and 85% will be apparently fine.6 Rates of all-cause death are expected to rise with no recognition of the new health threat injected — the COVID-19 vaccine.

We have a great show this week with our featured guest, Dr. Aseem Malhotra, MBBS, who is working to expose big pharma in the UK and worldwide. He is bright, young, articulate, and is in the British public eye and ”brings it” to the Report.

Original source: